Gene Therapy - Table of Contents alert Volume 22 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 22, Issue 2 (February 2015) In this issue Original Articles Short Communications Corrigendum Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Don't let your data go to waste...  Scientific Data helps researchers make the most of their data, offering publication in a peer reviewed open access journal. We welcome data of all sizes, from all areas of science. What's unique? A new type of article providing detailed descriptions of scientifically valuable datasets, maximising data discoverability and reuse. Discover what we can do for your data   Original Articles Top Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy C Hu, D S Tai, H Park, G Cantero, E Chan, M Yudkoff, S D Cederbaum and G S Lipshutz Gene Ther 2015 22: 111-115; advance online publication, December 4, 2014; 10.1038/gt.2014.106 Abstract | Full Text Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates M A Kotterman, L Yin, J M Strazzeri, J G Flannery, W H Merigan and D V Schaffer Gene Ther 2015 22: 116-126; advance online publication, December 11, 2014; 10.1038/gt.2014.115 Abstract | Full Text Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin T Nakama, S Yoshida, K Ishikawa, Y Kobayashi, Y Zhou, S Nakao, Y Sassa, Y Oshima, K Takao, A Shimahara, K Yoshikawa, T Hamasaki, T Ohgi, H Hayashi, A Matsuda, A Kudo, M Nozaki, Y Ogura, M Kuroda and T Ishibashi Gene Ther 2015 22: 127-137; advance online publication, December 11, 2014; 10.1038/gt.2014.112 Abstract | Full Text AAV-mediated and pharmacological induction of Hsp70 expression stimulates survival of retinal ganglion cells following axonal injury J M K Kwong, L Gu, N Nassiri, V Bekerman, R Kumar-Singh, K D Rhee, X-J Yang, W W Hauswirth, J Caprioli and N Piri Gene Ther 2015 22: 138-145; advance online publication, November 27, 2014; 10.1038/gt.2014.105 Abstract | Full Text Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma Y Shimazu, K Kurozumi, T Ichikawa, K Fujii, M Onishi, J Ishida, T Oka, M Watanabe, Y Nasu, H Kumon and I Date Gene Ther 2015 22: 146-154; advance online publication, November 13, 2014; 10.1038/gt.2014.100 Abstract | Full Text Tumor-specific suicide gene therapy for hepatocellular carcinoma by transcriptionally targeted retroviral replicating vectors Y-H Lai, C-C Lin, S-H Chen and C-K Tai Gene Ther 2015 22: 155-162; advance online publication, October 30, 2014; 10.1038/gt.2014.98 Abstract | Full Text Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses D Ivacik, A Ely, N Ferry and P Arbuthnot Gene Ther 2015 22: 163-171; advance online publication, October 23, 2014; 10.1038/gt.2014.94 Abstract | Full Text Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept C Leboeuf, J Roser-Schilder, M Lambotin, S Durand, T Wu, C Fauvelle, B Su, E Bôle-Richard, M Deschamps, C Ferrand, P Tiberghien, P Pessaux, T F Baumert and E Robinet Gene Ther 2015 22: 172-180; advance online publication, November 13, 2014; 10.1038/gt.2014.99 Abstract | Full Text Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease V J McCurdy, H E Rockwell, J R Arthur, A M Bradbury, A K Johnson, A N Randle, B L Brunson, M Hwang, H L Gray-Edwards, N E Morrison, J A Johnson, H J Baker, N R Cox, T N Seyfried, M Sena-Esteves and D R Martin Gene Ther 2015 22: 181-189; advance online publication, December 4, 2014; 10.1038/gt.2014.108 Abstract | Full Text Short Communications Top Adeno-associated virus inverted terminal repeats stimulate gene editing M L Hirsch Gene Ther 2015 22: 190-195; advance online publication, December 11, 2014; 10.1038/gt.2014.109 Abstract | Full Text AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy R Thwaite, G Pagès, M Chillón and A Bosch Gene Ther 2015 22: 196-201; advance online publication, November 20, 2014; 10.1038/gt.2014.103 Abstract | Full Text High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs J Pleticha, S A Malkmus, L F Heilmann, S L Veesart, R Rezek, Q Xu, T L Yaksh and A S Beutler Gene Ther 2015 22: 202-208; advance online publication, October 30, 2014; 10.1038/gt.2014.96 Abstract | Full Text The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies T Tsukahara, N Iwase, K Kawakami, M Iwasaki, C Yamamoto, K Ohmine, R Uchibori, T Teruya, H Ido, Y Saga, M Urabe, H Mizukami, A Kume, M Nakamura, R Brentjens and K Ozawa Gene Ther 2015 22: 209-215; advance online publication, November 27, 2014; 10.1038/gt.2014.104 Abstract | Full Text Corrigendum Top Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy C Hu, D S Tai, H Park, G Cantero, E Chan, M Yudkoff, S D Cederbaum and G S Lipshutz Gene Ther 2015 22: 216; 10.1038/gt.2014.127 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Gene Therapy. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.